Med1 plays a critical role in the development of tamoxifen resistance

Carcinogenesis

Volumn 33, Issue 4, 2012, Pages 918-930

  Nagalingam, Arumugam ^a   Tighiouart, Mourad ^b   Ryden, Lisa ^c   Joseph, Leena ^d   Landberg, Goran ^c,e   Saxena, Neeraj K ^f   Sharma, Dipali ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LUND UNIVERSITY   (Sweden)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; CELL PROTEIN; EBAG9 PROTEIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MED1 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN PS2; SERINE; SOMATOMEDIN C; TAMOXIFEN; TAMOXIFEN CITRATE; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG RESPONSE; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84859592969     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs105     Document Type: Article

References (64)

1. Platet, N. et al. (2004) Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit. Rev. Oncol. Hematol., 51, 55-67.
2. Baumann, C. K. et al. (2009) Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer. Minerva Ginecol., 61, 517-539.
3. Musgrove, E. A. et al. (2009) Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer, 9, 631-643.
4. Arpino, G. et al. (2009) Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. Oncology, 77 (suppl. 1), 23-37.
5. Welboren, W. J. et al. (2009) Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated? Endocr. Relat. Cancer, 16, 1073-1089.
6. Xu, J. et al. (2009) Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat. Rev. Cancer, 9, 615-630.
7. Kang, Y. K. et al. (2002) The TRAP/Mediator coactivator complex interacts directly with estrogen receptors alpha and beta through the TRAP220 subunit and directly enhances estrogen receptor function in vitro. Proc. Natl Acad. Sci. USA, 99, 2642-2647.
8. Belakavadi, M. et al. (2006) Role of the mediator complex in nuclear hormone receptor signaling. Rev. Physiol. Biochem. Pharmacol., 156, 23-43.
9. Chadick, J. Z. et al. (2005) Structure of eukaryotic Mediator complexes. Trends Biochem. Sci., 30, 264-271.
10. Conaway, J. W. et al. (2005) The mammalian Mediator complex. FEBS Lett., 579, 904-908.
11. Ren, Y. et al. (2000) Specific structural motifs determine TRAP220 interactions with nuclear hormone receptors. Mol. Cell. Biol., 20, 5433-5446.
12. Crawford, S. E. et al. (2002) Defects of the heart, eye, and megakaryocytes in peroxisome proliferator activator receptor-binding protein (PBP) null embryos implicate GATA family of transcription factors. J. Biol. Chem., 277, 3585-3592.
13. Frade, R. et al. (2000) RB18A, whose gene is localized on chromosome 17q12-q21. 1, regulates in vivo p53 transactivating activity. Cancer Res., 60, 6585-6589.
14. Gordon, D. F. et al. (2006) MED220/thyroid receptor-associated protein 220 functions as a transcriptional coactivator with Pit-1 and GATA-2 on the thyrotropin-beta promoter in thyrotropes. Mol. Endocrinol., 20, 1073-1089.
15. Stumpf, M. et al. (2006) The mediator complex functions as a coactivator for GATA-1 in erythropoiesis via subunit Med1/TRAP220. Proc. Natl Acad. Sci. USA, 103, 18504-18509.
16. Udayakumar, T. S. et al. (2006) Regulation of Aurora-A kinase gene expression via GABP recruitment of TRAP220/MED1. J. Biol. Chem., 281, 14691-14699.
17. Wada, O. et al. (2004) BRCA1 function mediates a TRAP/DRIP complex through direct interaction with TRAP220. Oncogene, 23, 6000-6005.
18. Sharma, D. et al. (2006) Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res., 66, 6370-6378.
19. Duquesnes, N. et al. (2009) The EGF receptor activates ERK but not JNK Ras-dependently in basal conditions but ERK and JNK activation pathways are predominantly Ras-independent during cardiomyocyte stretch. Int. J. Biochem. Cell Biol., 41, 1173-1181.
20. Brunner, N. et al. (1993) MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182, 780. Cancer Res., 53, 3229-3232.
21. Hu, X. F. et al. (1993) Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182, 780. Int. J. Cancer, 55, 873-876.
22. Taliaferro-Smith, L. et al. (2009) LKB1 is required for adiponectinmediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene, 28, 2621-2633.
23. Saxena, N. K. et al. (2007) Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res., 67, 2497-2507.
24. Saxena, N. K. et al. (2007) Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. J. Biol. Chem., 282, 13316-13325.
25. Xu, Y. et al. (2003) Neurite-localized estrogen receptor-alpha mediates rapid signaling by estrogen. J. Neurosci. Res., 74, 1-11.
26. Sharma, D. et al. (2000) Temporal formation of distinct thyroid hormone receptor coactivator complexes in HeLa cells. Mol. Endocrinol., 14, 2001-2009.
27. Sharma, D. et al. (2005) Release of methyl CpG binding proteins and histone deacetylase 1 from the estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol. Endocrinol., 19, 1740-1751.
28. Sharma, D. et al. (2002) Ordered recruitment of histone acetyltransferases and the TRAP/Mediator complex to thyroid hormone-responsive promoters in vivo. Proc. Natl Acad. Sci. USA, 99, 7934-7939.
29. Keen, J. C. et al. (2003) A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res. Treat., 81, 177-186.
30. Ryden, L. et al. (2005) Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur. J. Cancer, 41, 256-264.
31. Tsuneizumi, M. et al. (2001) Overrepresentation of the EBAG9 gene at 8q23 associated with early-stage breast cancers. Clin. Cancer Res., 7, 3526-3532.
32. Ellis, M. J. et al. (1998) Insulin-like growth factors in human breast cancer. Breast Cancer Res. Treat., 52, 175-184.
33. Klinge, C. M. (2001) Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res., 29, 2905-2919.
34. Tsuchiya, F. et al. (2001) Molecular cloning and characterization of mouse EBAG9, homolog of a human cancer associated surface antigen: expression and regulation by estrogen. Biochem. Biophys. Res. Commun., 284, 2-10.
35. Augereau, P. et al. (1994) Characterization of the proximal estrogenresponsive element of human cathepsin D gene. Mol. Endocrinol., 8, 693-703.
36. Dubik, D. et al. (1992) Mechanism of estrogen activation of c-myc oncogene expression. Oncogene, 7, 1587-1594.
37. Umayahara, Y. et al. (1994) Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J. Biol. Chem., 269, 16433-16442.
38. Pandey, P. K. et al. (2005) Activation of TRAP/mediator subunit TRAP220/Med1 is regulated by mitogen-activated protein kinase-dependent phosphorylation. Mol. Cell. Biol., 25, 10695-10710.
39. Lannigan, D. A. (2003) Estrogen receptor phosphorylation. Steroids, 68, 1-9.
40. Walker, R. A. (2008) Immunohistochemical markers as predictive tools for breast cancer. J. Clin. Pathol., 61, 689-696.
41. Ma, X. J. et al. (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell, 5, 607-616.
42. Iwase, H. (2003) Molecular action of the estrogen receptor and hormone dependency in breast cancer. Breast Cancer, 10, 89-96.
43. Hall, J. M. et al. (2005) Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol. Interv., 5, 343-357.
44. Gao, X. et al. (2002) The roles of sex steroid receptor coregulators in cancer. Mol. Cancer, 1, 7.
45. Hart, S. M. (2002) Modulation of nuclear receptor dependent transcription. Biol. Res., 35, 295-303.
46. Yuan, C. X. et al. (1998) The TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. Proc. Natl Acad. Sci. USA, 95, 7939-7944.
47. Malik, S. et al. (2004) Structural and functional organization of TRAP220, the TRAP/mediator subunit that is targeted by nuclear receptors. Mol. Cell. Biol., 24, 8244-8254.
48. Taatjes, D. J. et al. (2004) Structure and function of CRSP/Med2; a promoterselective transcriptional coactivator complex. Mol. Cell, 14, 675-683.
49. Belakavadi, M. et al. (2008) MED1 phosphorylation promotes its association with mediator: implications for nuclear receptor signaling. Mol. Cell. Biol., 28, 3932-3942.
50. Murphy, L. C. et al. (2011) Clinical significance of estrogen receptor phosphorylation. Endocr. Relat. Cancer, 18, R1-R14.
51. Kato, S. et al. (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science, 270, 1491-1494.
52. Campbell, R. A. et al. (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem., 276, 9817-9824.
53. Schiff, R. et al. (2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin. Cancer Res., 10, 331S-336S.
54. Kirkegaard, T. et al. (2005) AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J. Pathol., 207, 139-146.
55. Yamashita, H. et al. (2005) Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res., 7, R753-R764.
56. Murphy, L. C. et al. (2004) Phospho-serine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen. Clin. Cancer Res., 10, 5902-5906.
57. Jiang, J. et al. (2007) Phosphorylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin. Cancer Res., 13, 5769-5776.
58. Buzdar, A. U. (1998) Anastrozole: a new addition to the armamentarium against advanced breast cancer. Am. J. Clin. Oncol., 21, 161-166.
59. Ellis, M. J. et al. (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol., 19, 3808-3816.
60. Goss, P. E. et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med., 349, 1793-1802.
61. Colleoni, M. et al. (2003) Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase. Ann. Oncol., 14, 1477-1483.
62. Wong, S. T. (2009) Emerging treatment combinations: integrating therapy into clinical practice. Am. J. Health Syst. Pharm., 66, S9-S14.
63. Adamo, V. et al. (2007) Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. Ann. Oncol., 18 (suppl. 6), vi53-vi57.
64. Arpino, G. et al. (2008) Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr. Rev., 29, 217-233.